Burrill & Company closes second Burrill Capital Fund IV

Friday, August 3, 2012 02:32 PM

Burrill & Company, a global life sciences financial services firm, announced a second close of its Burrill Capital Fund IV, bringing the aggregate capital commitments to $505 million.

The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, healthcare delivery, wellness, and digital health.

"We are pleased that our new fund generated strong interest among investors," said G. Steven Burrill, CEO of Burrill & Company. "This is a time of great opportunities globally for investors in the life sciences, not just in traditional sectors, but emerging areas brought about by the convergence of healthcare and information technology."

Share:          
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs